CH643457A5 - PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. - Google Patents
PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. Download PDFInfo
- Publication number
- CH643457A5 CH643457A5 CH178579A CH178579A CH643457A5 CH 643457 A5 CH643457 A5 CH 643457A5 CH 178579 A CH178579 A CH 178579A CH 178579 A CH178579 A CH 178579A CH 643457 A5 CH643457 A5 CH 643457A5
- Authority
- CH
- Switzerland
- Prior art keywords
- active ingredients
- preparations according
- weight ratio
- occur
- preparations
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title description 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003826 tablet Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WRLKLPDTRUYBBV-UHFFFAOYSA-N 4-chloro-3-sulfamoylbenzamide Chemical compound NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 WRLKLPDTRUYBBV-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000054 salidiuretic effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Die Erfindung betrifft neue antihypertensive Präparate, The invention relates to new antihypertensive preparations,
die a) das 6-Benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido-[4,3-c]pyridazin, a) 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido- [4,3-c] pyridazine,
b) das 4-(2-Hydroxy-3-isopropylaminopropoxy)indol und c) das N-[cis-2',6'-DimethylpiperidyI-( 1 ')J-3-sulfamyl-4-chlorbenzoesäureamid enthalten, sowie die Herstellung dieser Präparate. b) the 4- (2-hydroxy-3-isopropylaminopropoxy) indole and c) the N- [cis-2 ', 6'-dimethylpiperidyl (1') J-3-sulfamyl-4-chlorobenzoic acid amide, and the preparation of these preparations.
Die unter a), b) und c) angeführten Wirkstoffe sind bekannt. The active ingredients listed under a), b) and c) are known.
Die erfindungsgemässen Präparate enthalten die Wirkstoffe a), b) und c) vorzugsweise in einem gewichtsmässigen Mengenverhältnis von ca. 0,5:1:1 bisca. 4:2:1, insbesondere ca. 1:2:1 oder ca. 1:1:1. Besonders bevorzugt ist das Verhältnis 1:2:1. The preparations according to the invention contain the active ingredients a), b) and c) preferably in a weight ratio of about 0.5: 1: 1 to approx. 4: 2: 1, especially approx. 1: 2: 1 or approx. 1: 1: 1. The ratio 1: 2: 1 is particularly preferred.
Erfindungsgemäss gelangt man zu den neuen Präparaten, indem man die Wirkstoffe in eine für therapeutische Zwecke geeignete Dosierungsform bringt. According to the invention, the new preparations are obtained by placing the active substances in a dosage form suitable for therapeutic purposes.
Die Wirkstoffe können in Form eines physiologisch verträglichen Salzes oder als freie Base verwendet werden. The active ingredients can be used in the form of a physiologically acceptable salt or as a free base.
a) sowie seine Salze zeichnet sich im Tierversuch bei einer Dosierung von ungefähr 0,1 bis 5 mg/kg Körpergewicht durch eine antihypertensive Wirkung aus, bewirkt aber im gleichen Dosisbereich eine dosisabhängige Tachykardie. a) and its salts are characterized in animal experiments at a dose of approximately 0.1 to 5 mg / kg of body weight by an antihypertensive effect, but cause dose-dependent tachycardia in the same dose range.
Durch die kombinierte Verabreichung von Wirkstoff b) mit Wirkstoff a) wird die antihypertensive Wirkung von a) verstärkt und die durch die Verbindung bedingte Tachykardie vermindert. The combined administration of active ingredient b) with active ingredient a) increases the antihypertensive effect of a) and reduces the tachycardia caused by the compound.
Dies kann durch Versuche am renal-hypertonen Hund (Methode nach Goldblatt) oder an der renal-hypertonen Ratte (Methode nach Grollmann) gezeigt werden. This can be shown by tests on the renally hypertensive dog (Goldblatt method) or on the renally hypertensive rat (Grollmann method).
Es wurde nun gefunden, dass durch die kombinierte Verabreichung von Wirkstoffen a) und b) mit einer dritten Komponente, dem Wirkstoff c), die Tendenz zur Ödembildung, die nach Verabreichung von a) mit b) eintreten kann, weitgehend unterdrückt wird. It has now been found that the combined administration of active ingredients a) and b) with a third component, the active ingredient c), largely suppresses the tendency towards edema formation which can occur after administration of a) with b).
Dieser Effekt ist mit der erfindungsgemässen Dreierkombination überraschend viel ausgeprägter als aufgrund der be-5 kannten salidiuretischen Wirkung von c) erwartet werden konnte. This effect is surprisingly much more pronounced with the combination of three according to the invention than could be expected from the known salidiuretic effect of c).
Für die Anwendung als Antihypertensiva, z. B. in der Hochdrucktherapie, variieren die zu verwendenden Dosen naturgemäss je nach Art der Verabreichung und des zu be-lo handelnden Zustandes. Im allgemeinen werden jedoch befriedigende Resultate mit einer täglichen Dosis von ca. 0,07 bis ca. 0,6 mg des Wirkstoffs a), ca. 0,14 bis ca. 0,3 mg des Wirkstoffs b) und ca. 0,07 bis ca. 0,14 mg des Wirkstoffs c) pro Kilo Körpergewicht erhalten; diese Dosis kann nötigen-15 falls in 2 bis 4 Anteilen oder auch als Retardform verabreicht werden. Für grössere Säugetiere liegt die Tagesdosis bei ca. 5 bis ca. 40 mg des Wirkstoffs a), ca. 10 bis ca. 20 mg des Wirkstoffs b) und ca. 5 bis ca. 10 mg des Wirkstoffs c). For use as an antihypertensive, e.g. B. in high pressure therapy, the doses to be used naturally vary depending on the type of administration and the condition to be treated. In general, however, satisfactory results are obtained with a daily dose of about 0.07 to about 0.6 mg of active ingredient a), about 0.14 to about 0.3 mg of active ingredient b) and about 0.07 up to about 0.14 mg of active ingredient c) per kilo of body weight; this dose can be administered if necessary in 2 to 4 portions or as a slow-release form. For larger mammals, the daily dose is about 5 to about 40 mg of the active ingredient a), about 10 to about 20 mg of the active ingredient b) and about 5 to about 10 mg of the active ingredient c).
Die Verabreichung erfolgt vorzugsweise einmal täglich. 20 Als Heilmittel kann die erfindungsgemässe Kombination allein oder in entsprechender Arzneiform für enterale oder parenterale Verabreichung verabreicht werden. Die Wirkstoffe können in einer Arzneiform vereinigt oder nebeneinander, z.B. in Form einer Doppelpackung, verwendet wer-25 den. It is preferably administered once a day. The combination according to the invention can be administered as a remedy alone or in a corresponding pharmaceutical form for enteral or parenteral administration. The active ingredients can be combined in a pharmaceutical form or side by side, e.g. in the form of a double pack, used.
Die Herstellung der erfindungsgemässen Kombination kann durch Mischung der Komponenten nach an sich bekannten Methoden erfolgen. Von praktischer Bedeutung ist dabei die für enterale Verabreichung geeignete Form, wie 30 z.B. Tabletten, Manteltabletten, Schichtentabletten, Kapseln, usw. The combination according to the invention can be produced by mixing the components according to methods known per se. The form suitable for enteral administration, such as e.g. Tablets, coated tablets, layered tablets, capsules, etc.
Geeignete pharmakologisch indifferente Hilfsstoffe für Tabletten und Kapseln sind z.B. Milchzucker, Stärke, Calciumsulfat, Talk, Magnesiumstearat. Suitable pharmacologically indifferent excipients for tablets and capsules are e.g. Milk sugar, starch, calcium sulfate, talc, magnesium stearate.
35 Ferner können sie noch andere Hilfsstoffe enthalten, wie Stabilisierungs- oder Netzmittel, Lösungsvermittler, Farbstoffe, usw. 35 They can also contain other auxiliaries, such as stabilizers or wetting agents, solubilizers, dyes, etc.
Säuren, die mit dem Wirkstoff a) geeignete physiologisch verträgliche Säureadditionssalze bilden, sind z.B. Chlor-40 wasserstoffsäure, Fumarsäure, Methansulfonsäure. Acids which form suitable physiologically compatible acid addition salts with the active ingredient a) are e.g. Chlorine-40 hydrochloric acid, fumaric acid, methanesulfonic acid.
Säuren, die mit dem Wirkstoff b) geeignete physiologisch verträgliche Säureadditionssalze bilden, sind z.B. Chlorwasserstoffsäure, Bromwasserstoffsäure, Schwefelsäure, Fumarsäure oder Maleinsäure. Acids which form suitable physiologically compatible acid addition salts with the active ingredient b) are e.g. Hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid or maleic acid.
45 Die aktiven Wirkstoffe a), b) und c) können sich gemeinsam in einer Verabreichungsform befinden, sie können jedoch ebenfalls getrennt, d.i. in zwei oder drei Verabreichungsformen in einer gemeinsamen Packung, enthalten sein, die jedoch so verabreicht werden, dass die gewünschte so Wirkung nach Verabreichung der drei Formen im Körper entsteht. 45 The active ingredients a), b) and c) can be together in one administration form, but they can also be separated, i.e. in two or three administration forms in a common package, which are administered in such a way that the desired effect is achieved after administration of the three forms in the body.
Das nachfolgende Beispiel erläutert die Erfindung. The following example explains the invention.
55 Beispiel: Tabletten 55 Example: tablets
6-Benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido- 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido-
[4,3-cJpyridazin (als Methansulfonat, [4,3-cJpyridazine (as methanesulfonate,
entspricht 10 mg Base) 13,5 mg corresponds to 10 mg base) 13.5 mg
4-(2-Hydroxy-3-isopropylaminopropoxy)indol 10 mg 60 N-[cis-2',6'-Dimethxylpiperidyl-(l ')]- 4- (2-hydroxy-3-isopropylaminopropoxy) indole 10 mg 60 N- [cis-2 ', 6'-dimethylpiperidyl- (l')] -
3-sulfamyl-4-chlorbenzoesäureamid 10 mg 3-sulfamyl-4-chlorobenzoic acid amide 10 mg
Milchzucker 62 mg Milk sugar 62 mg
Maisstärke 40 mg Corn starch 40 mg
Kolloidale Kieselsäure 5 mg Colloidal silica 5 mg
65 Polyvinylpyrrolidon .5 mg 65 polyvinylpyrrolidone. 5 mg
Talk -7 mg Talc -7 mg
Magnesiumstearat 1 mg Magnesium stearate 1 mg
153,5 mg 153.5 mg
3 3rd
643 457 643 457
Die Wirkstoffe werden mit dem Milchzucker, der kolloidalen Kieselsäure und einem Teil der Maisstärke gemischt. Die Mischung wird durch ein Sieb getrieben und mit einer alkoholischen Lösung von Polyvinylpyrrolidon geknetet. Diese wird durch ein Sieb getrieben, getrocknet und das trockene Granulat nochmals gesiebt. Darauf werden die restliche Maisstärke, Talk und Magnesiumstearat zugemischt und die Mischung zu Tabletten verpresst. The active ingredients are mixed with milk sugar, colloidal silica and part of the corn starch. The mixture is passed through a sieve and kneaded with an alcoholic solution of polyvinylpyrrolidone. This is driven through a sieve, dried and the dry granules are sieved again. The remaining corn starch, talc and magnesium stearate are then mixed in and the mixture is compressed into tablets.
Claims (6)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178579A CH643457A5 (en) | 1979-02-22 | 1979-02-22 | PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. |
| DE19803005029 DE3005029A1 (en) | 1979-02-22 | 1980-02-11 | ANTI-HYPERTENSIVE PHARMACEUTICAL PREPARATIONS |
| SE8001121A SE8001121L (en) | 1979-02-22 | 1980-02-13 | ANTI-HYPERTENSIVE PHARMACEUTICAL PREPARATIONS |
| GB8005245A GB2044101B (en) | 1979-02-22 | 1980-02-15 | Antihypertensive pharmaceutical compositions |
| BE1/9727A BE881763A (en) | 1979-02-22 | 1980-02-18 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF HYPERTENSION |
| NL8001000A NL8001000A (en) | 1979-02-22 | 1980-02-19 | METHODS FOR PREPARING A MEDICINE AGAINST HYPERTENSION AND FOR TREATING HYPERTENSION THEREOF |
| IL59432A IL59432A (en) | 1979-02-22 | 1980-02-20 | Anti-hypertensive compositions containing endralazin,a salidiuretic and pindolol |
| AU55742/80A AU538599B2 (en) | 1979-02-22 | 1980-02-20 | Compositions and treatment for hypertension |
| IE336/80A IE49073B1 (en) | 1979-02-22 | 1980-02-20 | Antihypertensive pharmaceutical compositions |
| CA000346083A CA1147657A (en) | 1979-02-22 | 1980-02-20 | Antihypertensive pharmaceutical compositions |
| NZ19978380A NZ199783A (en) | 1979-02-22 | 1980-02-20 | Sustained release compositions containing endralazine embedded in a wax matrix |
| PT70855A PT70855A (en) | 1979-02-22 | 1980-02-20 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
| FR8003669A FR2449450A1 (en) | 1979-02-22 | 1980-02-20 | NOVEL PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF HYPERTENSION |
| IT47950/80A IT1145433B (en) | 1979-02-22 | 1980-02-20 | PHARMACEUTICAL COMPOSITION USABLE FOR THE TREATMENT OF HYPERTENSION |
| NZ192924A NZ192924A (en) | 1979-02-22 | 1980-02-20 | Anti-hypertensive compositions containing endralazine, pendolol and a salidiuretic |
| HU80402A HU187271B (en) | 1979-02-22 | 1980-02-21 | Process for producing of medical preparates effecting fall in blood-pressure |
| PH23672A PH17118A (en) | 1979-02-22 | 1980-02-21 | Antihypertensive pharmaceutical compositions and its method of use |
| AT0095580A AT378915B (en) | 1979-02-22 | 1980-02-21 | METHOD FOR PRODUCING ANTI-HYPERTENSIVE PHARMACEUTICAL PREPARATIONS |
| JP1980480A JPS55115823A (en) | 1979-02-22 | 1980-02-21 | Antihypertensive pharmaceutic composition |
| ZA00801018A ZA801018B (en) | 1979-02-22 | 1980-02-22 | Antihypertensive pharmaceutical compositions |
| SE8202357A SE8202357L (en) | 1979-02-22 | 1982-04-15 | Antihypertensive compsns. free from side effects - contg. endralazine, a salidiuretic, esp. clopamide, and pindolol |
| MY619/85A MY8500619A (en) | 1979-02-22 | 1985-12-30 | Antihypertensive pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH178579A CH643457A5 (en) | 1979-02-22 | 1979-02-22 | PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH643457A5 true CH643457A5 (en) | 1984-06-15 |
Family
ID=4218544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH178579A CH643457A5 (en) | 1979-02-22 | 1979-02-22 | PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS55115823A (en) |
| AT (1) | AT378915B (en) |
| AU (1) | AU538599B2 (en) |
| BE (1) | BE881763A (en) |
| CA (1) | CA1147657A (en) |
| CH (1) | CH643457A5 (en) |
| DE (1) | DE3005029A1 (en) |
| FR (1) | FR2449450A1 (en) |
| GB (1) | GB2044101B (en) |
| HU (1) | HU187271B (en) |
| IE (1) | IE49073B1 (en) |
| IL (1) | IL59432A (en) |
| IT (1) | IT1145433B (en) |
| MY (1) | MY8500619A (en) |
| NL (1) | NL8001000A (en) |
| NZ (1) | NZ192924A (en) |
| PH (1) | PH17118A (en) |
| PT (1) | PT70855A (en) |
| SE (2) | SE8001121L (en) |
| ZA (1) | ZA801018B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2537434A1 (en) * | 1982-12-09 | 1984-06-15 | Sandoz Sa | Endralazine pharmaceutical composition in depot form |
| GB2367242B (en) * | 2000-09-21 | 2004-07-28 | Henderson Morley Res & Dev Ltd | Antiviral treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2458155A1 (en) * | 1973-12-19 | 1975-07-03 | Sandoz Ag | NEW PHARMACEUTICAL PREPARATIONS |
-
1979
- 1979-02-22 CH CH178579A patent/CH643457A5/en not_active IP Right Cessation
-
1980
- 1980-02-11 DE DE19803005029 patent/DE3005029A1/en active Granted
- 1980-02-13 SE SE8001121A patent/SE8001121L/en not_active Application Discontinuation
- 1980-02-15 GB GB8005245A patent/GB2044101B/en not_active Expired
- 1980-02-18 BE BE1/9727A patent/BE881763A/en not_active IP Right Cessation
- 1980-02-19 NL NL8001000A patent/NL8001000A/en not_active Application Discontinuation
- 1980-02-20 AU AU55742/80A patent/AU538599B2/en not_active Ceased
- 1980-02-20 NZ NZ192924A patent/NZ192924A/en unknown
- 1980-02-20 IT IT47950/80A patent/IT1145433B/en active
- 1980-02-20 PT PT70855A patent/PT70855A/en unknown
- 1980-02-20 IE IE336/80A patent/IE49073B1/en unknown
- 1980-02-20 FR FR8003669A patent/FR2449450A1/en active Granted
- 1980-02-20 IL IL59432A patent/IL59432A/en unknown
- 1980-02-20 CA CA000346083A patent/CA1147657A/en not_active Expired
- 1980-02-21 PH PH23672A patent/PH17118A/en unknown
- 1980-02-21 JP JP1980480A patent/JPS55115823A/en active Pending
- 1980-02-21 AT AT0095580A patent/AT378915B/en not_active IP Right Cessation
- 1980-02-21 HU HU80402A patent/HU187271B/en unknown
- 1980-02-22 ZA ZA00801018A patent/ZA801018B/en unknown
-
1982
- 1982-04-15 SE SE8202357A patent/SE8202357L/en not_active Application Discontinuation
-
1985
- 1985-12-30 MY MY619/85A patent/MY8500619A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IT1145433B (en) | 1986-11-05 |
| AT378915B (en) | 1985-10-25 |
| SE8202357L (en) | 1982-04-15 |
| HU187271B (en) | 1985-12-28 |
| ATA95580A (en) | 1985-03-15 |
| JPS55115823A (en) | 1980-09-06 |
| NL8001000A (en) | 1980-08-26 |
| IL59432A (en) | 1984-08-31 |
| PT70855A (en) | 1980-03-01 |
| ZA801018B (en) | 1981-09-30 |
| GB2044101B (en) | 1983-09-07 |
| IE49073B1 (en) | 1985-07-24 |
| DE3005029A1 (en) | 1980-09-04 |
| CA1147657A (en) | 1983-06-07 |
| SE8001121L (en) | 1980-08-23 |
| BE881763A (en) | 1980-08-18 |
| NZ192924A (en) | 1984-05-31 |
| IL59432A0 (en) | 1980-05-30 |
| MY8500619A (en) | 1985-12-31 |
| AU5574280A (en) | 1980-08-28 |
| FR2449450A1 (en) | 1980-09-19 |
| FR2449450B1 (en) | 1983-07-22 |
| GB2044101A (en) | 1980-10-15 |
| DE3005029C2 (en) | 1987-02-12 |
| PH17118A (en) | 1984-06-01 |
| IT8047950A0 (en) | 1980-02-20 |
| AU538599B2 (en) | 1984-08-23 |
| IE800336L (en) | 1980-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004010531T2 (en) | USE OF FUMIC ACID DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND ASTHMA | |
| DE69628415T2 (en) | MEDICINAL PRODUCTS CONTAINING MONOAMINE OXIDASE-B INHIBITORS | |
| WO2000059508A1 (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
| DE69737373T2 (en) | Estrogenic anticonvulsant | |
| EP0224810B1 (en) | Antihypertensive preparation containing a mixture | |
| EP0317855B1 (en) | Pharmaceutical products | |
| CH643457A5 (en) | PHARMACEUTICAL PREPARATIONS FOR TREATING HYPERTENSION. | |
| DE3008993A1 (en) | PHARMACEUTICAL PREPARATIONS | |
| DD209735A5 (en) | METHOD FOR THE PRODUCTION OF A NEW MEDICAMENT PREPARATION | |
| DD242349A5 (en) | PROCESS FOR PREPARING A SYNERGISTIC COMBINATION OF FLUPIRTIN AND 4-ACETAMIDO-PHENOL | |
| EP0524512B1 (en) | Antihypertensive combinations | |
| DE2621906C2 (en) | ||
| DE2347531A1 (en) | MEDICINAL PREPARATIONS FOR ORAL DIABETES TREATMENT | |
| DE2128730A1 (en) | Means to compensate for a dopamine deficiency in the brain | |
| DE2342214C3 (en) | Remedies | |
| DE1792271C3 (en) | Antihypertensive drug | |
| DE2059620C3 (en) | 2- (alpha- (p-chlorophenoxy) -isobutyryl) aminoethanesulfonic acid, its physiologically acceptable salts, processes for the preparation of these compounds and pharmacologically active preparations thereof | |
| CH652926A5 (en) | Pharmaceutical composition | |
| WO1992016229A1 (en) | Products containing verapamil and trandolapril | |
| DE2618500A1 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HIGH BLOOD PRESSURE | |
| DE2532180C2 (en) | Use of Etozolin in the fight against hypertension | |
| DE3317280C2 (en) | ||
| DE2830610A1 (en) | PHARMACEUTICAL COMPOSITION FOR INHIBITION OF PROLACTIN SECRETION | |
| DE2254018A1 (en) | NEW PHARMACEUTICAL PREPARATIONS | |
| DE3808835A1 (en) | Pharmaceutical composition containing a mixture of dihydroergotamine, etilefrine and troxerutin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |